Key regions: United Kingdom, Brazil, Europe, France, Canada
The Anti-Fibrinolytic Drugs market in Australia & Oceania has been experiencing steady growth in recent years.
Customer preferences: Patients with bleeding disorders, such as hemophilia, are the primary consumers of anti-fibrinolytic drugs. These drugs are also used in surgical procedures to prevent excessive bleeding. With an aging population and an increase in the number of surgeries performed, the demand for anti-fibrinolytic drugs has been on the rise.
Trends in the market: Australia has the largest market for anti-fibrinolytic drugs in the region, followed by New Zealand. The market in Australia is expected to continue to grow due to the increasing prevalence of bleeding disorders and the rise in surgical procedures. The market in New Zealand is also expected to grow, but at a slower pace. Other countries in the region, such as Fiji and Papua New Guinea, have smaller markets, but are also experiencing growth due to an increase in healthcare spending.
Local special circumstances: Australia has a well-established healthcare system and a high level of healthcare spending, which has contributed to the growth of the anti-fibrinolytic drugs market. The country also has a large aging population, which is more likely to require these drugs. In New Zealand, the market is smaller due to a lower population and healthcare spending. However, the country has a high incidence of bleeding disorders, which drives demand for these drugs.
Underlying macroeconomic factors: The growth of the anti-fibrinolytic drugs market in Australia & Oceania is primarily driven by demographic factors, such as an aging population and an increase in the number of surgeries performed. In addition, increasing healthcare spending in the region has contributed to the growth of the market. However, pricing pressures and the availability of generic drugs may limit the growth of the market in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
